Immunogenicity of Del19 EGFR mutations in Chinese patients affected by lung adenocarcinoma

Deng Pan, Dapeng Zhou, Weijing Cai, Weibo Wu, Wen Ling Tan, Caicun Zhou, Yanyan Lou

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Background: Mutant peptides presented by cancer cells are superior vaccine candidates than self peptides. The efficacy of mutant K-Ras, P53 and EGFR (Epidermal Growth Factor Receptor) peptides have been tested as cancer vaccines in pancreatic, colorectal, and lung cancers. The immunogenicity of EGFR Del19 mutations, frequent in Chinese lung adenocarcinoma patients, remains unclear. Results: We predicted the HLA binding epitopes of Del19 mutations of EGFR in Chinese lung adenocarcinoma patients with NetMHC software. Enzyme-linked immunosorbent assay (ELISA) was performed to detect the EGFR-reactive IgG in lung cancer patients. Del19 mutations may be presented by multiple HLA Class I molecules, with delE746_A750 presented by 37.5% of Chinese population. For HLA Class II molecules, Del19 mutations of EGFR may be presented by multiple HLA-DRB1 molecules, with delE746_A750 presented by 58.1% of Chinese population. Serum reactivity to wild type EGFR protein was significantly higher in patients with Del19 EGFR mutations than those with EGFR L858R point mutation or with EGFR wild type genotype. Conclusions: These findings suggest that Del19 mutations of EGFR, with an estimated frequency of 40% in Chinese lung adenocarcinoma patients, may serve as unique targets for immunotherapy in Chinese lung cancer patients.

Original languageEnglish (US)
Article number43
JournalBMC Immunology
Volume20
Issue number1
DOIs
StatePublished - Nov 13 2019

Keywords

  • INDEL
  • Immunotherapy
  • Lung cancer
  • Neo-antigen
  • PD1 checkpoint blocking antibody

ASJC Scopus subject areas

  • Immunology

Fingerprint Dive into the research topics of 'Immunogenicity of Del19 EGFR mutations in Chinese patients affected by lung adenocarcinoma'. Together they form a unique fingerprint.

Cite this